Lilly's gastric cancer drug meets late-stage goal
Oct 15 (Reuters) - Eli Lilly and Co said a late-stage study of its experimental gastric cancer drug met its main goal of improving overall survival.
The study, compared the drug ramucirumab to a placebo and the drug was tested as a second-line treatment in patients with cancers that originate in the stomach.
The study, named REGARD, also improved survival without the cancer worsening.
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source
- Radar showed missing plane may have turned back: Malaysia military
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Malaysian plane presumed crashed; questions over false IDs |
- Merkel raps Putin as Russian forces tighten grip on Crimea |